EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Equol Alleviates Postmenopausal Metabolic Dysfunction‐Associated Steatotic Liver Disease via the GPR30/PI3K Pathway

Hanqiang Cui, Bin Wang, Bo Zou, Guiming Zhang, Zhe Xu, Shuo Li, Jing Xu, Xiangmin Ni, Jian Wang

eFood · 2026-06 · 7 (3)

DOI: 10.1002/efd2.70148 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) in postmenopausal women underscores the need for effective preventive strategies. Equol (Eq) alleviates MASLD, yet its molecular mechanisms remain unknown. This study investigated Eq‐activated Nrf2 signaling pathways in postmenopausal MASLD. Molecular‐docking simulations were performed to investigate the interaction between Eq and G protein‐coupled estrogen receptor 30 (GPR30). Western blotting, qRT‐PCR, siRNA were employed to elucidate the mechanisms in the MASLD rat model and NaOL‐induced HepG2 cell model. Molecular‐docking simulations demonstrated that Eq strongly binds GPR30, enhancing nuclear translocation and the subsequent activation of PI3K/Nrf2. Eq ameliorated lipid accumulation and oxidative stress in NaOL‐treated HepG2 cells and the liver tissues of MASLD rats. In vitro, following Nrf2 siRNA treatment, Eq failed to alleviate oxidative stress in NaOL‐treated HepG2 cells, indicating that Nrf2 plays a critical role in its antioxidative effects. In vivo, Eq activated Nrf2 signaling and reduced oxidative stress in the livers of MASLD rats, potentially conferring protection against oxidative stress injury in high‐fat diet and ovariectomy treated SD rats. Notably, Eq treatment in the model groups significantly enhanced PI3K/Nrf2 phosphorylation. In summary, Eq binds to GPR30 and exerts a protective effect against MASLD by upregulating the PI3K/Nrf2 pathway.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →